Profile data is unavailable for this security.
About the company
ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
- Revenue in USD (TTM)8.38m
- Net income in USD-105.56m
- Incorporated2021
- Employees136.00
- LocationASP Isotopes Inc2200 Ross Avenue, Suite 4575EDALLAS 75201United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://aspisotopes.com/
More ▼
Mergers & acquisitions
| Acquired company | ASPI:NAQ since announced | Transaction value |
|---|---|---|
| Renergen Ltd | -28.99% | 107.22m |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elite Pharmaceuticals Inc | 140.12m | 43.41m | 441.57m | 68.00 | 10.59 | 5.49 | 9.81 | 3.15 | 0.0387 | 0.0387 | 0.1268 | 0.0748 | 1.29 | 3.03 | 4.18 | 2,060,564.00 | 39.98 | 13.18 | 45.86 | 16.01 | 51.06 | 47.19 | 30.98 | 13.97 | 5.44 | -- | 0.0517 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 455.63m | 31.00 | -- | 19.70 | -- | 6.48 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 463.33m | 46.00 | 6.25 | 2.28 | 6.17 | 2.69 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Invivyd Inc | 50.04m | -59.86m | 476.56m | 99.00 | -- | 3.89 | -- | 9.52 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 488.01m | 142.00 | -- | -- | -- | 11.25 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 502.74m | 59.00 | 15.11 | 3.77 | 12.36 | 5.96 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Ironwood Pharmaceuticals, Inc. | 296.15m | 24.02m | 557.66m | 100.00 | 31.72 | -- | 21.53 | 1.88 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| CorMedix Inc | 214.30m | 162.50m | 561.77m | 64.00 | 3.47 | 1.49 | 3.37 | 2.62 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 630.58m | 162.00 | 5.63 | 5.36 | 5.45 | 2.24 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 668.09m | 136.00 | -- | 6.73 | -- | 79.69 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 785.60m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 800.86m | 304.00 | -- | -- | -- | 2.64 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Pacira Biosciences Inc | 726.41m | 7.03m | 887.13m | 829.00 | 139.48 | 1.30 | 9.04 | 1.22 | 0.1571 | 0.1571 | 16.19 | 16.86 | 0.5155 | 1.08 | 6.12 | 876,249.70 | 0.4991 | 0.0898 | 0.5891 | 0.1062 | 79.39 | 74.50 | 0.9683 | 0.221 | 3.28 | -- | 0.3494 | 0.00 | 3.63 | 11.07 | 107.07 | -45.44 | -16.51 | -- |
Data as of Feb 27 2026. Currency figures normalised to ASP Isotopes Inc's reporting currency: US Dollar USD
32.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Encompass Capital Advisors LLCas of 16 Jan 2026 | 6.41m | 5.13% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.20m | 4.95% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.53m | 4.42% |
| A.K. Jensen Investment Management Ltd.as of 30 Sep 2025 | 4.96m | 3.96% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 4.90m | 3.91% |
| Rovida Investment Management Ltd.as of 31 Dec 2025 | 4.10m | 3.28% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.38m | 1.91% |
| UBS Securities LLCas of 31 Dec 2025 | 2.20m | 1.76% |
| AWM Investment Co., Inc.as of 31 Dec 2025 | 2.12m | 1.70% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.84m | 1.47% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
